Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure
Authors:
- 1 February 2014
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 171 (3) , 398-403
Abstract
No abstract availableKeywords
Funding Information
- Gout Research Foundation of Japan
- Tottori University
- Ministry of Education, Culture, Sports, Science and Technology (25461057)
This publication has 35 references indexed in Scilit:
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- The Association of Hemoglobin A1c With Incident Heart Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities StudyDiabetes, 2010
- Spironolactone Improves Glucose and Lipid Metabolism by Ameliorating Hepatic Steatosis and Inflammation and Suppressing Enhanced Gluconeogenesis Induced by High-Fat and High-Fructose DietEndocrinology, 2010
- Insulin Resistance Is Highly Prevalent and Is Associated With Reduced Exercise Tolerance in Nondiabetic Patients With Heart FailureJACC, 2009
- Aldosterone Inhibits Insulin-Induced Glucose Uptake by Degradation of Insulin Receptor Substrate (IRS) 1 and IRS2 via a Reactive Oxygen Species-Mediated Pathway in 3T3-L1 AdipocytesEndocrinology, 2008
- Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart FailureJACC, 2005
- Insulin Resistance and Risk of Congestive Heart FailureJAMA, 2005
- The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial InfarctionCardiovascular Drugs and Therapy, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Insulin Resistance in Chronic Heart Failure: Relation to Severity and Etiology of Heart FailureJACC, 1997